Bio-markers of disease activity and response to therapy in multiple sclerosis
Authors:
- Ariel MillerAMAriel Miller
- Lea Glass-MarmorLGLea Glass-Marmor
- Michal AbrahamMAMichal Abraham
- Iris GrossmanIGIris Grossman
- Sarah ShapiroSSSarah Shapiro
- Yanina GalboizYGYanina Galboiz
- 1 June 2004
- journal article
- review article
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 106 (3) , 249-254
Abstract
No abstract availableThis publication has 69 references indexed in Scilit:
- Serum uric acid and multiple sclerosisNeurological Sciences, 2002
- The role of uric acid in protection against peroxynitrite-mediated pathologyMedical Hypotheses, 2001
- Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosisMultiple Sclerosis Journal, 2000
- Metalloproteinases and their Tissue Inhibitors in Multiple SclerosisJournal of Autoimmunity, 1999
- Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosisBrain, 1999
- Regulation of self-tolerance by CD80/CD86 interactionsCurrent Opinion in Immunology, 1997
- Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.Journal of Clinical Investigation, 1997
- Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopyBrain, 1996
- Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions.Journal of Experimental Medicine, 1995
- Immune‐mediated demyelinationAnnals of Neurology, 1993